These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7773777)

  • 1. Solution structure of the tetrameric minimum transforming domain of p53.
    Lee W; Harvey TS; Yin Y; Yau P; Litchfield D; Arrowsmith CH
    Nat Struct Biol; 1994 Dec; 1(12):877-90. PubMed ID: 7773777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.
    Clore GM; Omichinski JG; Sakaguchi K; Zambrano N; Sakamoto H; Appella E; Gronenborn AM
    Science; 1994 Jul; 265(5170):386-91. PubMed ID: 8023159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA.
    Klein C; Planker E; Diercks T; Kessler H; Künkele KP; Lang K; Hansen S; Schwaiger M
    J Biol Chem; 2001 Dec; 276(52):49020-7. PubMed ID: 11606582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.
    McCoy M; Stavridi ES; Waterman JL; Wieczorek AM; Opella SJ; Halazonetis TD
    EMBO J; 1997 Oct; 16(20):6230-6. PubMed ID: 9321402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the p53 core domain dimer bound to DNA.
    Ho WC; Fitzgerald MX; Marmorstein R
    J Biol Chem; 2006 Jul; 281(29):20494-502. PubMed ID: 16717092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain.
    Brokx RD; Bolewska-Pedyczak E; Gariépy J
    J Biol Chem; 2003 Jan; 278(4):2327-32. PubMed ID: 12433927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Cho Y; Gorina S; Jeffrey PD; Pavletich NP
    Science; 1994 Jul; 265(5170):346-55. PubMed ID: 8023157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
    Lee AS; Galea C; DiGiammarino EL; Jun B; Murti G; Ribeiro RC; Zambetti G; Schultz CP; Kriwacki RW
    J Mol Biol; 2003 Mar; 327(3):699-709. PubMed ID: 12634062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.
    Poon GM; Brokx RD; Sung M; Gariépy J
    J Mol Biol; 2007 Jan; 365(4):1217-31. PubMed ID: 17113101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.
    Gorina S; Pavletich NP
    Science; 1996 Nov; 274(5289):1001-5. PubMed ID: 8875926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solution conformation of an essential region of the p53 transactivation domain.
    Botuyan MV; Momand J; Chen Y
    Fold Des; 1997; 2(6):331-42. PubMed ID: 9427007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution.
    Zhao K; Chai X; Johnston K; Clements A; Marmorstein R
    J Biol Chem; 2001 Apr; 276(15):12120-7. PubMed ID: 11152481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain.
    D'Abramo M; Bešker N; Desideri A; Levine AJ; Melino G; Chillemi G
    Oncogene; 2016 Jun; 35(25):3272-81. PubMed ID: 26477317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refined solution structure of the oligomerization domain of the tumour suppressor p53.
    Clore GM; Ernst J; Clubb R; Omichinski JG; Kennedy WM; Sakaguchi K; Appella E; Gronenborn AM
    Nat Struct Biol; 1995 Apr; 2(4):321-33. PubMed ID: 7796267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.
    Jeffrey PD; Gorina S; Pavletich NP
    Science; 1995 Mar; 267(5203):1498-502. PubMed ID: 7878469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of a p53 core tetramer bound to DNA.
    Malecka KA; Ho WC; Marmorstein R
    Oncogene; 2009 Jan; 28(3):325-33. PubMed ID: 18978813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.
    Shieh SY; Taya Y; Prives C
    EMBO J; 1999 Apr; 18(7):1815-23. PubMed ID: 10202145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and functionality of a designed p53 dimer.
    Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
    J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case.
    Ithuralde RE; Turjanski AG
    PLoS One; 2016; 11(1):e0144284. PubMed ID: 26742101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
    Luciani MG; Hutchins JR; Zheleva D; Hupp TR
    J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.